We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Nebulized ensifentrine, an investigational inhaled anti-inflammatory, reduced exacerbations of chronic obstructive pulmonary disease (COPD) by 42 percent over 24 weeks — a significant benefit that could propel Verona Pharma to submit regulatory documents for a first-in-class treatment. Read More
GlaxoSmithKline (GSK) and clinical-stage biopharma company Mersana Therapeutics have forged a global collaboration, giving GSK the exclusive option to codevelop and commercialize Mersana’s antibody-drug conjugate (ADC) XMT-2056 targeting HER2. Read More
The company initially plans to offer the robotic system for use in knee replacement surgeries but is also planning to develop other orthopedic applications in the near future. Read More